SPUNOLEUCEL

UNII:	EVQ94BW5G4
Type:	INGREDIENT SUBSTANCE
Formula:
Preferred Substance Name:	SPUNOLEUCEL
GSRS Full Record:	EVQ94BW5G4 i

ALV-106
ALVR106
ALVR106 is a novel virus-specific cell-based therapy to treat four respiratory viral infections that are a serious cause of morbidity and mortality in immunocompromised patients. ALVR106 is under development to treat four respiratory viral infections (respiratory syncytial virus, influenza, parainfluenza virus and human metapneumovirus) that are common and of significant clinical concern in immunocompromised patients, including those who have undergone hematopoietic stem cell transplantation, solid organ transplantation, as well as in vulnerable elderly and pediatric populations
ALVR106 is a polyclonal (CD4+ and CD8+) virus-specific T cell product containing cells that are reactive against four viruses (RSV, Influenza, PIV, and hMPV). The cells are derived from peripheral blood mononuclear cells (PBMCs) from donors seropositive for all four of these viruses
ALVR106 is comprised of both CD8+ and CD4+ virus-specific T cells capable of recognizing actively replicating virus-infected cells, proliferating in response to antigenic stimulation and mediating antiviral effects including the production of cytokines and effector molecules, killing of infected cells in patients with infections/diseases associated with the target viruses
Allogeneic Multi-Virus Specific T Lymphocytes Targeting Respiratory Syncytial Virus (RSV), Influenza, Parainfluenza Virus (PIV), and Human Metapneumovirus (hMPV)
SPUNOLEUCEL [USAN]
Spunoleucel
spunoleucel [INN]

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.

SPUNOLEUCEL

Synonyms and Mappings

Resources